Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: chimeric antigen receptor T-cell therapeutics - Celyad Oncology

Next Previous
Search
Drug Profile

Research programme: chimeric antigen receptor T-cell therapeutics - Celyad Oncology

Alternative Names: CAR NKp/B7H6; CAR-NKp30/B7H6; CAR-T NKG2Dß; CAR-T NKp30; CYAD-04; CYAD-05; NKR-3 Allogeneic; NKR-3 Autologous; TCR-deficient NKR T-cell therapy - Celyad Oncology

Latest Information Update: 28 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dartmouth College
  • Developer Celyad Oncology
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 28 Apr 2025 No recent reports of development identified for preclinical development in Cancer in Belgium (Parenteral, Infusion)
  • 06 Apr 2023 Early research is ongoing in Belgium for Cancer (Celyad Oncology pipeline; April 2023)
  • 04 Aug 2022 Research programme: chimeric antigen receptor T-cell therapeutics - Celyad Oncology is available for licensing as of 04 Aug 2022. https://celyad.com/

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top